Thelansis

 Dyskeratosis Congenita (DC) is a rare genetic syndrome characterized by nail, skin, and oral issues, along with a heightened risk of bone marrow failure and cancer. It results from mutations in various genes linked to telomere biology. DKC1 mutations cause X-linked recessive DC, while autosomal dominant genes involved are TERC, TERT, TINF2, RTEL1, PARN, and ACD. Autosomal recessive genes include TERT, NHP2, NOP10, RTEL1, WRAP53, and ACD, with CTC1, POT1, and STN1 as rare causes. DC presents with nail abnormalities, skin changes, and oral leukoplakia in childhood and may lead to bone marrow failure and cancer. Diagnosis involves telomere length testing, and management includes regular check-ups and, in the case of bone marrow failure, hematopoietic stem cell transplantation, or androgen therapy. Life expectancy varies, with a significant risk of bone marrow failure, cancer, and pulmonary complications.   Thelansis’s “Dyskeratosis Congenita (DC) Market Outlook, Epidemiology...

 Dyskeratosis Congenita (DC) is a rare ectodermal dysplasia syndrome characterised by the classic triad of nail dysplasia, skin pigmentary changes, and oral leukoplakia, as well as a high risk of bone marrow failure (BMF) and cancer. Thelansis’s “Dyskeratosis Congenita (DC) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dyskeratosis Congenita (DC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Dyskeratosis Congenita (DC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, fut...